199 related articles for article (PubMed ID: 24423618)
1. World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.
Klinguer-Hamour C; Strop P; Shah DK; Ducry L; Xu A; Beck A
MAbs; 2014; 6(1):18-29. PubMed ID: 24423618
[TBL] [Abstract][Full Text] [Related]
2. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.
Beck A; Lambert J; Sun M; Lin K
MAbs; 2012; 4(6):637-47. PubMed ID: 22909934
[TBL] [Abstract][Full Text] [Related]
3. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
Beck A; Senter P; Chari R
MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
[TBL] [Abstract][Full Text] [Related]
4. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
Beck A; Wurch T; Reichert JM
MAbs; 2011; 3(2):111-32. PubMed ID: 21441785
[TBL] [Abstract][Full Text] [Related]
5. Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.
Wurch T; Larbouret C; Robert B
MAbs; 2009; 1(4):318-25. PubMed ID: 20068403
[TBL] [Abstract][Full Text] [Related]
6. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
7. Site-specific antibody drug conjugates for cancer therapy.
Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
[TBL] [Abstract][Full Text] [Related]
8. American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.
Thudium K; Bilic S; Leipold D; Mallet W; Kaur S; Meibohm B; Erickson H; Tibbitts J; Zhao H; Gupta M
MAbs; 2013; 5(1):5-12. PubMed ID: 23255090
[TBL] [Abstract][Full Text] [Related]
9. Antibody drug conjugates: lessons from 20 years of clinical experience.
Tolcher AW
Ann Oncol; 2016 Dec; 27(12):2168-2172. PubMed ID: 27733376
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the development and manufacturing of antibody-drug conjugates.
Ducry L
Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
[TBL] [Abstract][Full Text] [Related]
11. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
12. World Endometriosis Society consensus on the classification of endometriosis.
Johnson NP; Hummelshoj L; Adamson GD; Keckstein J; Taylor HS; Abrao MS; Bush D; Kiesel L; Tamimi R; Sharpe-Timms KL; Rombauts L; Giudice LC;
Hum Reprod; 2017 Feb; 32(2):315-324. PubMed ID: 27920089
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
14. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies.
Amani N; Dorkoosh FA; Mobedi H
Curr Drug Deliv; 2020; 17(1):23-51. PubMed ID: 31755387
[TBL] [Abstract][Full Text] [Related]
15. IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.
Marquardt J; Begent RH; Chester K; Huston JS; Bradbury A; Scott JK; Thorpe PE; Veldman T; Reichert JM; Weiner LM
MAbs; 2012; 4(6):648-52. PubMed ID: 23007482
[TBL] [Abstract][Full Text] [Related]
16. 4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.
Beck A; Hanala S; Reichert JM
MAbs; 2009; 1(2):93-103. PubMed ID: 20061813
[TBL] [Abstract][Full Text] [Related]
17. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.
Kalim M; Chen J; Wang S; Lin C; Ullah S; Liang K; Ding Q; Chen S; Zhan J
Drug Des Devel Ther; 2017; 11():2265-2276. PubMed ID: 28814834
[TBL] [Abstract][Full Text] [Related]
18. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.
Gerber HP; Koehn FE; Abraham RT
Nat Prod Rep; 2013 May; 30(5):625-39. PubMed ID: 23525375
[TBL] [Abstract][Full Text] [Related]
19. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
